Pasithea Therapeutics (KTTA) Short Interest Ratio & Short Volume $0.94 +0.01 (+1.05%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$0.94 0.00 (-0.11%) As of 05/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock Pasithea Therapeutics Short Interest DataPasithea Therapeutics (KTTA) has a short interest of 44,300 shares, representing 1.85% of the float (the number of shares available for trading by the public). This marks a -89.37% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 2.07 million shares to cover all short positions.Current Short Interest44,300 sharesPrevious Short Interest416,900 sharesChange Vs. Previous Month-89.37%Dollar Volume Sold Short$73,538.00Short Interest Ratio0.0 Days to CoverLast Record DateApril 30, 2025Outstanding Shares2,958,000 sharesFloat Size2,390,000 sharesShort Percent of Float1.85%Today's Trading Volume361,212 sharesAverage Trading Volume2,068,627 sharesToday's Volume Vs. Average17% Short Selling Pasithea Therapeutics? Sign up to receive the latest short interest report for Pasithea Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKTTA Short Interest Over TimeKTTA Days to Cover Over TimeKTTA Percentage of Float Shorted Over Time Pasithea Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202544,300 shares $73,538.00 -89.4%1.9%0 $1.66 4/15/2025416,900 shares $550,308.00 +2,795.1%19.0%0.2 $1.32 3/31/202514,400 shares $18,720.00 +82.3%0.7%0 $1.30 3/15/20257,900 shares $8,769.00 -9.2%0.8%0 $1.11 2/28/20258,700 shares $10,092.00 -67.4%0.9%0 $1.16 2/15/202526,700 shares $38,715.00 +641.7%2.6%0 $1.45 1/31/20253,600 shares $8,064.00 -64.7%0.4%0 $2.24 1/15/202510,200 shares $25,092.00 -60.5%1.0%0.2 $2.46 12/31/202425,800 shares $81,270.00 +37.2%2.5%0.6 $3.15 12/15/202418,800 shares $49,820.00 -22.3%1.8%0 $2.65 Get the Latest News and Ratings for KTTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/202424,200 shares $74,778.00 +374.5%2.4%0 $3.09 11/15/20245,100 shares $17,238.00 -56.0%0.6%0 $3.38 10/31/202411,600 shares $44,080.00 -49.1%1.5%0 $3.80 10/15/202422,800 shares $90,060.00 -86.7%2.8%0 $3.95 9/30/2024171,300 shares $928,446.00 +42,725.0%21.4%0.2 $5.42 9/15/2024400 shares $1,548.00 -90.7%0.1%0 $3.87 8/31/20244,300 shares $19,570.16 -45.6%0.5%0.3 $4.55 8/15/20247,900 shares $36,261.00 +182.1%1.0%0.7 $4.59 7/31/20242,800 shares $14,700.00 -31.7%0.4%0.3 $5.25 7/15/20244,100 shares $24,846.41 -34.9%0.6%1.2 $6.06 6/30/20246,300 shares $31,882.41 -28.4%0.9%2.2 $5.06 6/15/20248,800 shares $46,288.00 -8.3%1.2%2.7 $5.26 5/31/20249,600 shares $52,416.00 -4.0%1.3%4.2 $5.46 5/15/202410,000 shares $66,500.00 No Change1.3%4.8 $6.65 4/30/202410,000 shares $69,200.00 No Change1.3%3 $6.92 4/15/202410,000 shares $71,500.00 +14.9%1.3%2 $7.15 3/31/20248,700 shares $63,077.61 +3.6%1.2%1 $7.25 3/15/20248,400 shares $58,575.72 -8.7%0.1%0.7 $6.97 2/29/20249,200 shares $73,600.00 +4.6%0.1%0.1 $8.00 2/15/20248,800 shares $62,524.00 -5.4%0.1%0.1 $7.11 1/31/20249,300 shares $60,915.00 -31.1%0.1%0.1 $6.55 1/15/202413,500 shares $101,385.00 +29.8%0.1%0.2 $7.51 12/31/202310,400 shares $76,960.00 -98.1%0.1%0.1 $7.40 12/15/2023539,600 shares $188,860.00 +1,652.0%3.6%0.3 $0.35 11/30/202330,800 shares $10,040.80 -13.7%0.2%0.8 $0.33 11/15/202335,700 shares $11,781.00 -2.5%0.2%1.2 $0.33 10/31/202336,600 shares $12,810.00 -13.3%0.2%1 $0.35 10/15/202342,200 shares $18,568.00 +29.5%0.2%0.8 $0.44 9/30/202332,600 shares $15,638.22 -40.0%0.2%0.2 $0.48 9/15/202354,300 shares $27,150.00 -55.7%0.3%0.3 $0.50The Trump Dump is starting; Get out of stocks now? (Ad)The first 365 days of the Trump presidency… Will be the best time to get rich in American history.If I’m right about this (like I was before) a modest $900 investment could grow to a life-changing a 8/31/2023122,600 shares $74,234.30 -24.1%0.6%0.6 $0.61 8/15/2023161,500 shares $97,788.25 +111.1%0.8%0.7 $0.61 7/31/202376,500 shares $45,754.65 +4.2%0.4%0.3 $0.60 7/15/202373,400 shares $34,211.74 -26.0%0.4%0.3 $0.47 6/30/202399,200 shares $48,608.00 -32.4%0.5%0.8 $0.49 6/15/2023146,800 shares $67,997.76 +149.2%0.8%1.6 $0.46 5/31/202358,900 shares $20,615.00 -2.0%0.3%0.7 $0.35 5/15/202360,100 shares $21,041.01 +39.4%0.3%1.2 $0.35 4/30/202343,100 shares $15,080.69 +24.9%0.2%0.7 $0.35 4/15/202334,500 shares $13,458.45 +37.5%0.2%0.5 $0.39 3/31/202325,100 shares $9,412.50 -60.8%0.2%0.3 $0.38 3/15/202364,100 shares $30,133.41 +357.9%0.5%0.7 $0.47 2/28/202314,000 shares $6,721.40 +25.0%0.1%0.1 $0.48 2/15/202311,200 shares $6,287.74 -78.8%0.1%0.1 $0.56 1/31/202352,900 shares $37,180.77 -64.2%0.4%0.6 $0.70 1/15/2023147,900 shares $103,027.29 -12.9%1.1%2.1 $0.70 12/30/2022169,800 shares $108,960.66 -13.7%1.3%1.8 $0.64 12/15/2022196,700 shares $155,786.40 -6.2%1.5%1.8 $0.79 11/30/2022209,800 shares $207,743.96 +10.8%1.6%1.9 $0.99 11/15/2022189,300 shares $194,979.00 -16.1%1.5%1.4 $1.03 10/31/2022225,600 shares $245,904.00 -36.8%1.7%0.5 $1.09 10/15/2022356,700 shares $445,875.00 +44.1%2.7%0.7 $1.25 9/30/2022247,600 shares $311,976.00 -17.0%1.7%0.5 $1.26 9/15/2022298,200 shares $357,840.00 +20.2%2.0%0.6 $1.20 8/31/2022248,200 shares $285,430.00 -69.0%1.7%0.5 $1.15 8/15/2022800,000 shares $1.04 million +386.0%5.5%1.7 $1.30 7/31/2022164,600 shares $190,936.00 +13.4%1.5%1 $1.16 7/15/2022145,200 shares $162,624.00 -23.9%1.3%0.9 $1.12 6/30/2022190,900 shares $192,809.00 -9.3%1.7%1.3 $1.01 6/15/2022210,400 shares $212,504.00 +124.6%1.5%1.2 $1.01 5/31/202293,700 shares $80,347.75 -17.5%0.7%0.4 $0.86 5/15/2022113,600 shares $103,353.28 -6.0%0.8%0.4 $0.91 4/30/2022120,900 shares $145,080.00 -35.7%0.9%0.3 $1.20 4/15/2022188,100 shares $253,935.00 -30.8%1.4%0.3 $1.35 3/31/2022271,800 shares $353,340.00 -39.3%2.0%0.4 $1.30 3/15/2022447,700 shares $555,148.00 +0.5%5.6%0.2 $1.24 2/28/2022445,400 shares $454,308.00 -19.9%5.6%0.1 $1.02 2/15/2022555,700 shares $683,511.00 +5.9%6.9%0.1 $1.23 1/31/2022524,900 shares $677,121.00 +43.0%6.5%0.1 $1.29 1/15/2022367,000 shares $506,460.00 -64.0%4.5%0.1 $1.38 12/31/20211,020,000 shares $1.81 million No Change22.1%0.2 $1.77 KTTA Short Interest - Frequently Asked Questions What is Pasithea Therapeutics' current short interest? Short interest is the volume of Pasithea Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 44,300 shares of KTTA short. 1.85% of Pasithea Therapeutics' shares are currently sold short. Learn More on Pasithea Therapeutics' current short interest. What is a good short interest percentage for Pasithea Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.85% of Pasithea Therapeutics' floating shares are currently sold short. Is Pasithea Therapeutics' short interest increasing or decreasing? Pasithea Therapeutics saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 44,300 shares, a decline of 89.4% from the previous total of 416,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Pasithea Therapeutics' float size? Pasithea Therapeutics currently has issued a total of 2,958,000 shares. Some of Pasithea Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Pasithea Therapeutics currently has a public float of 2,390,000 shares. How does Pasithea Therapeutics' short interest compare to its competitors? 1.85% of Pasithea Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Pasithea Therapeutics: Cyclerion Therapeutics, Inc. (2.69%), Kiora Pharmaceuticals, Inc. (1.03%), Phio Pharmaceuticals Corp. (5.78%), Sensei Biotherapeutics, Inc. (2.41%), Biomerica, Inc. (1.89%), Creative Medical Technology Holdings, Inc. (1.78%), Addex Therapeutics Ltd (0.35%), Acurx Pharmaceuticals, Inc. (1.81%), Portage Biotech Inc. (69.97%), Ainos, Inc. (62.88%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Pasithea Therapeutics stock? Short selling KTTA is an investing strategy that aims to generate trading profit from Pasithea Therapeutics as its price is falling. KTTA shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Pasithea Therapeutics? A short squeeze for Pasithea Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of KTTA, which in turn drives the price of the stock up even further. How often is Pasithea Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KTTA, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies CYCN Short Squeeze KPRX Short Squeeze PHIO Short Squeeze SNSE Short Squeeze BMRA Short Squeeze CELZ Short Squeeze ADXN Short Squeeze ACXP Short Squeeze PRTG Short Squeeze AIMD Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KTTA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KTTA Stock Free KTTA Stock Alerts